“For an industry that traditionally has taken a conservative approach to adopting emerging technologies, life science organizations (LSOs) were thrust into the digital era almost overnight,” Gartner notes in the latest Hype CycleTM report1. In response to the pandemic, these organizations “immediately accelerated the application of advanced analytics technologies to personalize customer engagement, deploy new digital channels, advance patient-engagement strategies and pursue new health value creation opportunities.”
But with the leap toward newfound technology adoption comes the challenge of scale. As CIOs continue to hone their long-term technology strategies, understanding the maturity level and efficiency of each product in their portfolio is paramount. “Because the path forward is uncertain, CIOs will need to develop a technology strategy that is adaptable, scalable and resilient to meet new business requirements on demand,” Gartner states.
To ensure the success of their investments in digital tools and solutions, life sciences organizations are forming more partnerships across the healthcare ecosystem. In the prescribed digital therapeutics (PDTs) sector, Gartner suggests that companies “seek partnerships with technology vendors that have the capabilities to develop and scale the technologies needed for digital therapeutic deployment.” The report further notes that, “The success of PDTs depends on identifying the right commercial model and partners that have aligned incentives, cultural fit, defined expectations and open communications.”
As CIOs continue to build advanced analytics, one thing is certain: the life sciences industry is heading toward a platform approach. "We expect digital life science platforms to be mainstream in the next five to 10 years, enabling them to nimbly adapt their business and operating models in response to external disruption and change in business strategy.”
To provide CIOs with the input they need to prioritize innovation and balance revenue, cost and value, Gartner has released “Hype Cycle for Life Science Commercial Operations, 2021.” In it, Gartner assesses the LSO technology ecosystem, analyzing products’ capabilities at different stages of maturity, from “Innovation Trigger” to “Plateau of Productivity.” The report recognizes ZS as a Sample Vendor in 5 technologies, including the Life Science Personalization Engine and the Commercial Data & Analytics Platform.
1. Gartner, Hype Cycle for Life Science Commercial Operations, 2021, Animesh Gandhi, 14 July 2021
Gartner does not endorse any vendor, product or service depicted in its research publications, and does not advise technology users to select only those vendors with the highest ratings or other designation. Gartner research publications consist of the opinions of Gartner's research organization and should not be construed as statements of fact. Gartner disclaims all warranties, expressed or implied, with respect to this research, including any warranties of merchantability or fitness for a particular purpose.
Gartner and Hype Cycle are registered trademarks of Gartner, Inc. and/or its affiliates in the U.S. and internationally and is used herein with permission. All rights reserved.